Nonacus Email Format
Biotechnology ResearchEngland, United Kingdom11-50 Employees
Nonacus is a biotechnology company based in Birmingham, England, United Kingdom, with 11-50 employees and ISO 9001 certification. It develops a precision oncology workflow that supports both primary tumor analysis and liquid biopsy, with the aim of enabling earlier cancer diagnosis and management. The GALEAS product range includes GALEAS Bladder, a non-invasive urine test for bladder cancer; GALEAS Tumor for comprehensive genomic profiling; and the GALEAS HereditaryPlus panel for inherited cancer-related mutations. Nonacus operates Nonacus Clinical Services, a UK laboratory delivering genomic cancer testing to the NHS and private providers, and has formed collaborations with clinicians and institutions such as The London Clinic Limited. Product launches in the GALEAS line have included GALEAS Bladder in 2023, GALEAS HereditaryPlus in 2024, and GALEAS Tumor in 2024, with reported revenue in the data ranging from $1 million to $10 million.